GlassScriptPhysician profile
Julie D Brack
NPI 1396836680
$3,639.55
in general payments reported to CMS, 2019-2025
46 companies · $747 in 2025
The $747 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $255 · 2022: $762 · 2023: $1,059 · 2024: $816 · 2025: $747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,622.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $677.77 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $437.20 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $331.19 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.20 | 2021-2024 | Jardiance, Tradjenta, Synjardy |
| Astrazeneca Pharmaceuticals LP | $155.50 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $148.89 | 2022-2025 | Evenity, Prolia, Otezla |
| Pfizer INC. | $148.56 | 2022-2025 | |
| Glaxosmithkline, LLC. | $128.41 | 2022-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Lundbeck LLC | $107.44 | 2024-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $87.41 | 2022-2023 | Belsomra, Steglatro, Steglujan |
| Novartis Pharmaceuticals Corporation | $78.74 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.29 | 2022-2023 | Gattex, Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $70.75 | 2022-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.20 | 2023-2024 | Xifaxan |
| Ibsa Pharma INC. | $59.01 | 2023 | Tirosint, Licart |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Brack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.